TY - JOUR PY - 2000 DA - 2000// TI - A prevalence study of primary dystonia in eight European countries JO - J Neurol VL - 247 ID - ref1 ER - TY - JOUR AU - Jankovic, J. AU - Tsui, J. AU - Bergeron, C. PY - 2007 DA - 2007// TI - Prevalence of cervical dystonia and spasmodic torticollis in the United States general population JO - Parkinsonism Relat Disord VL - 13 ID - Jankovic2007 ER - TY - JOUR AU - Castelao, M. AU - Marques, R. E. AU - Duarte, G. S. AU - Rodrigues, F. B. AU - Ferreira, J. AU - Sampaio, C. PY - 2017 DA - 2017// TI - Botulinum toxin type a therapy for cervical dystonia JO - Cochrane Database Syst Rev VL - 12 ID - Castelao2017 ER - TY - JOUR AU - Chan, J. AU - Brin, M. F. AU - Fahn, S. PY - 1991 DA - 1991// TI - Idiopathic cervical dystonia: clinical characteristics JO - Mov Disord VL - 6 ID - Chan1991 ER - TY - JOUR AU - Contarino, M. F. AU - Dool, J. AU - Balash, Y. AU - Bhatia, K. AU - Giladi, N. AU - Koelman, J. H. PY - 2017 DA - 2017// TI - Clinical practice: evidence-based recommendations for the treatment of cervical dystonia with Botulinum toxin JO - Front Neurol VL - 8 ID - Contarino2017 ER - TY - JOUR AU - Poewe, W. AU - Burbaud, P. AU - Castelnovo, G. AU - Jost, W. H. AU - Ceballos-Baumann, A. O. AU - Banach, M. PY - 2016 DA - 2016// TI - Efficacy and safety of abobotulinumtoxinA liquid formulation in cervical dystonia: a randomized-controlled trial JO - Mov Disord VL - 31 ID - Poewe2016 ER - TY - JOUR AU - Simonetta-Moreau, M. AU - Picaut, P. AU - Volteau, M. AU - Poewe, W. PY - 2019 DA - 2019// TI - Quality of life improvements in patients with cervical dystonia following treatment with a liquid formulation of abobotulinumtoxinA (Dysport((R)) ) JO - Eur J Neurol VL - 26 ID - Simonetta-Moreau2019 ER - TY - JOUR AU - Truong, D. AU - Duane, D. D. AU - Jankovic, J. AU - Singer, C. AU - Seeberger, L. C. AU - Comella, C. L. PY - 2005 DA - 2005// TI - Efficacy and safety of botulinum type a toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study JO - Mov Disord VL - 20 ID - Truong2005 ER - TY - JOUR AU - Truong, D. AU - Brodsky, M. AU - Lew, M. AU - Brashear, A. AU - Jankovic, J. AU - Molho, E. PY - 2010 DA - 2010// TI - Long-term efficacy and safety of botulinum toxin type a (Dysport) in cervical dystonia JO - Parkinsonism Relat Disord VL - 16 ID - Truong2010 ER - TY - JOUR AU - Chapman, M. A. AU - Barron, R. AU - Tanis, D. C. AU - Gill, C. E. AU - Charles, P. D. PY - 2007 DA - 2007// TI - Comparison of botulinum neurotoxin preparations for the treatment of cervical dystonia JO - Clin Ther VL - 29 ID - Chapman2007 ER - TY - JOUR AU - Ferrari, A. AU - Manca, M. AU - Tugnoli, V. AU - Alberto, L. PY - 2018 DA - 2018// TI - Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal JO - Funct Neurol VL - 33 ID - Ferrari2018 ER - TY - JOUR AU - Odergren, T. AU - Hjaltason, H. AU - Kaakkola, S. AU - Solders, G. AU - Hanko, J. AU - Fehling, C. PY - 1998 DA - 1998// TI - A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia JO - J Neurol Neurosurg Psychiatry VL - 64 ID - Odergren1998 ER - TY - JOUR AU - Ranoux, D. AU - Gury, C. AU - Fondarai, J. AU - Mas, J. L. AU - Zuber, M. PY - 2002 DA - 2002// TI - Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia JO - J Neurol Neurosurg Psychiatry VL - 72 ID - Ranoux2002 ER - TY - JOUR AU - Rystedt, A. AU - Zetterberg, L. AU - Burman, J. AU - Nyholm, D. AU - Johansson, A. PY - 2015 DA - 2015// TI - A comparison of Botox 100 U/mL and Dysport 100 U/mL using dose conversion ratio 1: 3 and 1: 1.7 in the treatment of cervical dystonia: a double-blind, randomized, crossover trial JO - Clin Neuropharmacol VL - 38 ID - Rystedt2015 ER - TY - JOUR AU - Yun, J. Y. AU - Kim, J. W. AU - Kim, H. T. AU - Chung, S. J. AU - Kim, J. M. AU - Cho, J. W. PY - 2015 DA - 2015// TI - Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study JO - Mov Disord VL - 30 ID - Yun2015 ER - TY - STD TI - Misra VP, Ehler E, Zakine B, Maisonobe P, Simonetta-Moreau M, group IIC. Factors influencing response to Botulinum toxin type A in patients with idiopathic cervical dystonia: results from an international observational study. BMJ Open. 2012;2(3). ID - ref16 ER - TY - JOUR AU - Jen, M. H. AU - Kurth, H. AU - Iheanacho, I. AU - Dinet, J. AU - Gabriel, S. AU - Wasiak, R. PY - 2014 DA - 2014// TI - Assessing the burden of illness from cervical dystonia using the Toronto Western spasmodic torticollis rating scale scores and health utility: a meta-analysis of baseline patient-level clinical trial data JO - J Med Econ VL - 17 ID - Jen2014 ER - TY - JOUR AU - Rowen, D. AU - Brazier, J. AU - Roberts, J. PY - 2009 DA - 2009// TI - Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? JO - Health Qual Life Outcomes VL - 7 ID - Rowen2009 ER - TY - STD TI - Groupement pour l’Elaboration et la Réalisation de Statistiques (GERS). Data on file. 2018. ID - ref19 ER - TY - JOUR AU - Charles, D. AU - Brashear, A. AU - Hauser, R. A. AU - Li, H. I. AU - Boo, L. M. AU - Brin, M. F. PY - 2012 DA - 2012// TI - Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia JO - Clin Neuropharmacol VL - 35 ID - Charles2012 ER - TY - JOUR AU - Comella, C. L. AU - Jankovic, J. AU - Truong, D. D. AU - Hanschmann, A. AU - Grafe, S. PY - 2011 DA - 2011// TI - Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(R), botulinum neurotoxin type a, without accessory proteins) in patients with cervical dystonia JO - J Neurol Sci VL - 308 ID - Comella2011 ER - TY - JOUR AU - Poewe, W. AU - Deuschl, G. AU - Nebe, A. AU - Feifel, E. AU - Wissel, J. AU - Benecke, R. PY - 1998 DA - 1998// TI - What is the optimal dose of botulinum toxin a in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German dystonia study group JO - J Neurol Neurosurg Psychiatry VL - 64 ID - Poewe1998 ER - TY - JOUR AU - Wissel, J. AU - Kanovsky, P. AU - Ruzicka, E. AU - Bares, M. AU - Hortova, H. AU - Streitova, H. PY - 2001 DA - 2001// TI - Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type a haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study JO - J Neurol VL - 248 ID - Wissel2001 ER - TY - JOUR AU - Trosch, R. M. AU - Shillington, A. C. AU - English, M. L. AU - Marchese, D. PY - 2015 DA - 2015// TI - A retrospective, single-center comparative cost analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for cervical dystonia treatment JO - J Manag Care Spec Pharm VL - 21 ID - Trosch2015 ER - TY - JOUR AU - Kazerooni, R. AU - Broadhead, C. PY - 2015 DA - 2015// TI - Cost-utility analysis of botulinum toxin type a products for the treatment of cervical dystonia JO - Am J Health-Syst Pharm VL - 72 ID - Kazerooni2015 ER - TY - JOUR AU - Berger, M. L. AU - Sox, H. AU - Willke, R. J. AU - Brixner, D. L. AU - Eichler, H. G. AU - Goettsch, W. PY - 2017 DA - 2017// TI - Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making JO - Pharmacoepidemiol Drug Saf VL - 26 ID - Berger2017 ER - TY - JOUR AU - Johnson, M. L. AU - Crown, W. AU - Martin, B. C. AU - Dormuth, C. R. AU - Siebert, U. PY - 2009 DA - 2009// TI - Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR good research practices for retrospective database analysis task force report--part III JO - Value Health VL - 12 ID - Johnson2009 ER - TY - JOUR AU - Breukelen, G. J. PY - 2006 DA - 2006// TI - ANCOVA versus change from baseline: more power in randomized studies, more bias in nonrandomized studies [corrected] JO - J Clin Epidemiol VL - 59 ID - Breukelen2006 ER -